pravastatin/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Increases serum adiponectin
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“By pooling the results of the nine included comparisons, our meta-analysis showed that pravastatin treatment was associated with a significant increased level of circulating adiponectin as compared with controls (WMD =0.63 µg/mL; 95% CI, 0.17–1.09 µg/mL; P=0.007; Figure 2A), with moderate heterogeneity among the included studies (P for Cochrane’s Q test =0.20, I =28%).”
Quoted verbatim from Effect of pravastatin treatment on circulating adiponectin: a meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- Eight randomized controlled trials (nine comparisons) of patients with various disease statuses (hyperlipidemia, type 2 diabetes, metabolic syndrome, coronary artery disease), pravastatin versus control; total adiponectin measured by ELISA or radioimmunoassay
Effect 0.63 mean difference, 95% CI 0.17 to 1.09
Effect of pravastatin treatment on circulating adiponectin: a meta-analysis of randomized controlled trials.2019PMID:31190742Permalink
Keep reading
- Everything the graph holds on pravastatin
- Every compound studied against Serum adiponectin
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M45EG838CRHJGKGNVJVGMN8V